Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A Phase 1/2 Study of WT1 Peptide Cancer Vaccine WT4869 in Patients with Myelodysplastic Syndromes (MDS)

Takahiro Suzuki, MD PhD, Yasunori Ueda, MD PhD, Michinori Ogura, MD PhD, Toshiki Uchida, MD PhD, Keiya Ozawa, MD PhD, Shigesaburo Miyakoshi, MDPhD, Tomoki Naoe, MD PhD, Makoto Murata, MD PhD, Masahiro Kizaki, MD PhD, Naokuni Uike, MD, Yasunobu Abe, MD PhD, Michihiro Hidaka, MD PhD, Shuzo Tagashira, Satoru Tsuchiya, Kazuma Ohyashiki, MD PhD, Yasushi Miyazaki, MD PhD

Blood (2015) 126 (23): 2868.

https://doi.org/10.1182/blood.V126.23.2868.2868

Published: 2015

Journal Articles

Multicenter Phase II Study of Lenalidomide in Patients with Relapsed Adult T-Cell Leukemia-Lymphoma

Hiroshi Fujiwara, MD PhD, Takashi Ishida, MD PhD, Kisato Nosaka, MD PhD, Naoya Taira, MD, Yasunobu Abe, MD PhD, Yoshitaka Imaizumi, MD PhD, Yukiyoshi Moriuchi, MD, Tatsuro Jo, MD PhD, Kenichi Ishizawa, MD, PhD, Kensei Tobinai, MD PhD, Kunihiro Tsukasaki, MD PhD, Shigeki Ito, MD PhD, Makoto Yoshimitsu, Maki Otsuka, Michinori Ogura, MD, Shuichi Midorikawa, PhD, Wanda Ruiz, PhD, Tomoko Ohtsu, MD

Blood (2015) 126 (23): 181.

https://doi.org/10.1182/blood.V126.23.181.181

Published: 2015

Journal Articles

Two Phase I and Pharmacokinetic Studies of Darinaparsin (Organic Arsenic Compound) in Japanese and Korean Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)

Won-Seog Kim, MD PhD, Michinori Ogura, MD PhD, Toshiki Uchida, MD PhD, Naokuni Uike, MD, PhD, Yasunobu Abe, MD PhD, Kenichi Ishizawa, MD, PhD, Yoko Okitsu, MD PhD, Kensei Tobinai, MD PhD, Fumiko Nagahama, Yusuke Sonehara, Hirokazu Nagai, MD PhD

Blood (2015) 126 (23): 2714.

https://doi.org/10.1182/blood.V126.23.2714.2714

Published: 2015

Journal Articles

Minimal Residual Disease Negative Status At the End of Induction Therapy Is a Potent Prognostic Marker in Adult Non-Ph Acute Lymphoblastic Leukemia: Results of the ALL MRD2002 Study

Koji Nagafuji, MD, PhD, Toshihiro Miyamoto, MD, PhD, Tetsuya Eto, MD, PhD, Tomohiko Kamimura, MD, Shuichi Taniguchi, MD, PhD, Takashi Okamura, MD, PhD, Eiichi Ohtsuka, MD, PhD, Takashi Yoshida, MD, Masakazu Higuchi, MD, PhD, Goichi Yoshimoto, MD, PhD, Tomoaki Fujisaki, MD, PhD, Yasunobu Abe, MD, PhD, Yasushi Takamatsu, MD, PhD, Shouhei Yokota, MD, PhD, Koichi Akashi, MD, PhD., Mine Harada, MD, PhD

Blood (2011) 118 (21): 2581.

https://doi.org/10.1182/blood.V118.21.2581.2581

Published: 2011

Journal Articles

Hemophagocytic Lymphohistiocytosis Is Caused by Engulfment of Hematopoietic Stem Cells by Macrophages Through Stem Cell-Specific Suppression of CD47 Under Influence of Cytokine Deregulation

Takuro Kuriyama, MD, Katsuto Takenaka, MD, PhD, Kentaro Kohno, MD, Goichi Yoshimoto, MD, PhD, Junji Kishimoto, PhD, Yasunobu Abe, MD, PhD, Toshihiro Miyamoto, MD, PhD, Koichi Akashi, MD, PhD.

Blood (2011) 118 (21): 522.

https://doi.org/10.1182/blood.V118.21.522.522

Published: 2011

Journal Articles

Mortalin-2 (mthsp70/PBP74/Grp75) Mediates the Erythropoietin Signal To Stimulate Growth of Purified Human Erythroid Progenitor Cells.

Rie Ohtsuka, MD, Yasunobu Abe, MD,PhD, Tomomi Fujii, PhD, Junji Nishimura, MD,PhD, Koichiro Muta, MD,PhD

Blood (2006) 108 (11): 4165.

https://doi.org/10.1182/blood.V108.11.4165.4165

Published: 2006

Journal Articles

Mortalin-2 (mthsp70/PBP74/Grp75), a Novel Mediator of Erythropoietin Signal.

Rie Ohtsuka, MD, Yasunobu Abe, MD, PhD, Tomomi Fujii, PhD, Eriko Nagasawa, MD, Hirotoshi Shimada, MD, Yoshimichi Tachikawa, MD, Koichiro Muta, MD, PhD

Blood (2005) 106 (11): 3141.

https://doi.org/10.1182/blood.V106.11.3141.3141

Published: 2005

NARROW

A Phase 1/2 Study of WT1 Peptide Cancer Vaccine WT4869 in Patients with Myelodysplastic Syndromes (MDS)

Multicenter Phase II Study of Lenalidomide in Patients with Relapsed Adult T-Cell Leukemia-Lymphoma

Two Phase I and Pharmacokinetic Studies of Darinaparsin (Organic Arsenic Compound) in Japanese and Korean Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)

Minimal Residual Disease Negative Status At the End of Induction Therapy Is a Potent Prognostic Marker in Adult Non-Ph Acute Lymphoblastic Leukemia: Results of the ALL MRD2002 Study

Hemophagocytic Lymphohistiocytosis Is Caused by Engulfment of Hematopoietic Stem Cells by Macrophages Through Stem Cell-Specific Suppression of CD47 Under Influence of Cytokine Deregulation

Mortalin-2 (mthsp70/PBP74/Grp75) Mediates the Erythropoietin Signal To Stimulate Growth of Purified Human Erythroid Progenitor Cells.

Mortalin-2 (mthsp70/PBP74/Grp75), a Novel Mediator of Erythropoietin Signal.

Email alerts

ASH Publications

American Society of Hematology

A Phase 1/2 Study of WT1 Peptide Cancer Vaccine WT4869 in Patients with Myelodysplastic Syndromes (MDS)

Multicenter Phase II Study of Lenalidomide in Patients with Relapsed Adult T-Cell Leukemia-Lymphoma

Two Phase I and Pharmacokinetic Studies of Darinaparsin (Organic Arsenic Compound) in Japanese and Korean Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)

Minimal Residual Disease Negative Status At the End of Induction Therapy Is a Potent Prognostic Marker in Adult Non-Ph Acute Lymphoblastic Leukemia: Results of the ALL MRD2002 Study

Hemophagocytic Lymphohistiocytosis Is Caused by Engulfment of Hematopoietic Stem Cells by Macrophages Through Stem Cell-Specific Suppression of CD47 Under Influence of Cytokine Deregulation

Mortalin-2 (mthsp70/PBP74/Grp75) Mediates the Erythropoietin Signal To Stimulate Growth of Purified Human Erythroid Progenitor Cells.

Mortalin-2 (mthsp70/PBP74/Grp75), a Novel Mediator of Erythropoietin Signal.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only